Please assess the completion status of the following clinical trial:

Trial Title: Colchicine in COVID-19: a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent for participation in the study~* Virological diagnosis of SARS-CoV-2 infection (real-time PCR)~* Hospitalized due to clinical/instrumental diagnosis of pneumonia~* Oxygen saturation at rest in ambient air ≤94%~* PaO2/FiO2 ratio of 350 to 200~Exclusion Criteria:~* Known hypersensitivity to colchicine or its excipients~* Severe diarrhea~* Patients who cannot take oral therapy~* Pregnant and lactating patients~* Patients with severe cardiac, renal insufficiency (creatinine clearance (CCL) \<30 mL / min)~* Patients with kidney or liver damage \[(AST or ALT\> 5 times the normal limits in International Units (ULN)\]; or are taking CYP3A4 enzyme - P glycoprotein inhibitors.~* Known other clinical condition that contraindicates colchicine and cannot be treated or solved according to the judgement of the clinician~* Neutrophils \<1.000 / mmc~* Platelets \<50.000 / mmc~* Bowel diverticulitis or perforation~* Patients already in ICU or requiring mechanical ventilation~* Patients receiving Tocilizumab~* Patients already enrolled in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colchicine plus current care (Type: EXPERIMENTAL): Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
- Current care alone (Type: NO_INTERVENTION): Current care

Based on this trial design, predict the completion outcome and termination type (if applicable).